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Summary Carcinoembryonic antigen (CEA) is a well-known tumour marker whose immunohistochemical expression could be prognostically
relevant in breast carcinomas. We evaluated CEA immunohistochemical expression, using the specific T84.66 monoclonal antibody, in a
series of 252 consecutive cases of infiltrating breast carcinomas (104 NO, 148 N1/2) with median follow-up of 84 months. Oestrogen receptor
(ER) status has been evaluated with the immunohistochemical method (ER1D5 antibody, 10% cut-off value): 121 cases were ER negative,
128 cases were ER positive and in three cases ER status was unknown. CEA staining was cytoplasmic; staining intensity and percentage of
reacting cells were combined to obtain a final score (CEA score). The difference between the distribution of CEA score within the modalities
of the other variables was not statistically significant. Univariate survival analysis has been performed on the series of node-negative and
node-positive patients. In the latter subgroup, this has been performed separately for patients treated with systemic adjuvant hormonal
therapy or chemotherapy. A multivariate analysis was only performed for node-positive patients treated with adjuvant therapy. CEA
immunoreactivity was not prognostically relevant in any subset of analysed patients. The most important prognostic markers were nodal
status and tumour size.
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Carcinoembryonic antigen (CEA) is a well-known and widely
studied serological tumour marker. Several studies suggested that
its evaluation could provide valuable clinical information in
patients affected by breast carcinoma (Molina et al, 1995), but data
are still not conclusive (ASCO, 1996). CEA expression has also
been studied with immunohistochemical methods on large series
of breast carcinomas, but its meaning as a prognostic marker
remains unclear (Walker, 1980; Kuhajda et al, 1983; Mansour et al,
1983; Eskelinen et al, 1992). Discrepant results are indeedreported
in the literature: this may be partly because of the wide variety of
antibodies used, some ofwhich may not be completely specific for
the CEA molecule and cross-react with other molecules. CEA
belongs to a family of related molecules with several epitopes,
many of which are shared by molecules of other families. The
recently raised T84.66 monoclonal antibody is a CEA-specific
reagent that does not cross-react with other molecules (Neumeier
et al, 1990; Esteban et al, 1993). This antibody has been used to
investigate the prognostic value of CEA immunoreactivity in two
series of breast carcinomas, but again results seem to be
conflicting (Esteban et al, 1994; Sundblad et al, 1996). In the study
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ofEsteban et al (1994) CEA immunostaining per se was not prog-
nostically relevant, whereas in the study of Sundblad et al (1996)
CEA immunostaining was an independent predictor of disease-
free survival. One of the suggestions of the study of Esteban et al
(1994) was that the combination ofCEA expression and ER status
may identify a subgroup ofpatients at higher risk ofdisease recur-
rence or death.
In the present paper we have evaluated the immunohistochem-
ical expression of CEA in a series of 252 breast carcinomas using
the same T84.66 antibody. The aim was to evaluate its potential
prognostic value in relation to conventional clinicopathological
parameters and ER status.
MATERIAL AND METHODS
Patients
We investigated 252 consecutive patients with breast carcinomas
who had undergone surgery from January 1984 to November
1990. The study period ended by November 1995. The main
clinicopathological features ofthe patients are listed in Table 1.
Eligibility criteria were: histological diagnosis of infiltrating
breast carcinoma, axillary lymph node dissection, pathological
tumour size pTl-pT3, no distant metastasis (MO), unilateral breast
cancer and no other previous or concomitant primary cancer. The
patients were staged according to the International Union Against
Cancer Tumour Node Metastasis (UICC-TNM) Classification.
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Table 1 Characteristics of the patients










Min, Ql, median, Q3, maxb 20, 45, 54.5, 65, 82
ND 2
.55 years 130 51.6
> 55 years 122 48.4
Number of involved nodes


















aTwelve infiltrating lobular carcinomas, five medullary carcinomas, seven
infiltrating tubular carcinomas, seven mucinous carcinomas and four
cribriform infiltrating carcinoma. bMin, minimum; Ql, 25% quantile; Q3, 75%
quantile; max, maximum. cOestrogen receptor status. ND, not determined.
The median follow-up duration of the patients was 84 months
(range 6-140 months) for relapse-free survival (RFS) and 86
months (range 11-146 months) for overall survival (OS).
Adjuvant treatments
A total of 163 patients received adjuvant systemic therapy
according to the risk ofrelapse (positive nodal status, negative ER
status, high nuclear grade). A total of82 patients (73 node-positive
and nine node-negative) were treated with chemotherapy based on
the CMF scheme (oral schedule: cyclophosphamide 100 mg m-2
p.o. on days 1-14, methotrexate 40 mg m-2 i.v. on days 1 and 8,
5-fluorouracil 600 mg m-2 i.v. on days 1 and 8, every 4 weeks for
six courses; i.v. schedule: cyclophosphamide 600 mg m-2 on day 1,
methotrexate 40 mg m-2 on day 1, 5-fluorouracil 600 mg m-2 on
day 1, every 3 weeks for eight courses). A total of 73 patients (65
node-positive and eight node-negative) received adjuvant hormonal
therapy with a daily oral dose of 20-40 mg of tamoxifen. Eight
node-positive patients were treated with both hormonal and
chemotherapy. Two node-positive patients did not receive any
adjuvant treatment.
Follow-up
All patients were followed up after surgical treatment. Physical
examination was performed monthly during adjuvant
chemotherapy and every 4 months in all women for the first 3
years and then twice per year. Radiographic studies (chest radiog-
raphy, liver echotomography, bone scan, mammography) were
carried out every 12 months or earlier, whenever clinically indi-
cated. Haematological tests, including 12-channel biochemical
profiles and complete blood cell counts, were repeated at every
follow-up check. RFS and OS were calculated as the period from
surgery until the date of the first recurrence (RFS) or death (OS)
respectively.
Tumour samples
Surgical samples were collected shortly after surgical removal,
fixed in buffered formalin for 24-48 h at room temperature and
were routinely processed; cases were classified as follows: 217
(86.1%) infiltrating ductal carcinomas and 12 (4.8%) infiltrating
lobular carcinomas; five (1.9%) medullary carcinomas; seven
(2.8%) infiltrating tubular carcinomas; seven (2.8%) mucinous
carcinomas; and four (1.6%) cribriform infiltrating carcinoma.
Carcinomas classified in the last five histotypes (35 carcinomas,
13.9%) were jointly considered as others (Table 1). Tumour
grading, according to Elston and Ellis (1991), was performed by
two pathologists (MB, MB) working at the same institution.
Immunohistochemistry
Immunostaining was performed on paraffin sections of primary
tumours. Briefly, 4-,um paraffin sections were treated with the
microwave antigen retrieval system, incubated for 1-12 h at room
temperature with the primary antibodies and processed using the
StreptABC technique (Dako, Glostrup, Denmark). Primary anti-
CEA monoclonal antibody T84.66 was used at 1:800 dilution, and
was a generous gift from Dr Battifora (Duarte, CA, USA). Primary
anti-ER antibody (ERlD5, Dako Glostrup) was used at 1:100 dilu-
tion. Negative controls were obtained by omitting primary anti-
bodies. Cells were considered positive for CEA only when clear
cytoplasmic staining was seen. Cells were considered positive for
ER only when distinct nuclear staining was identified. The
percentage ofimmunoreactive cells was evaluated by scanning the
whole sections at medium and high magnification, and by
counting at least 1000 cells. For CEA we also evaluated the
staining intensity, which was scored as follows: 0 no staining; 1 +
weak; 2 + moderate; and 3 + strong staining. A final score (CEA
score) was obtained by multiplying the percentage ofreacting cells
with their staining intensity. Cases were considered positive for
ER when the percentage ofreacting cells was higher than 10%.
Statistical analysis
The distribution ofCEA score within the modalities ofeach ofthe
other variables was compared using the Kolmogorov-Smirnov test
(KST). The pattern of OS and RFS were estimated using the
product limit method (Kaplan-Meier). The role of each of the
prognostic variables (univariate analysis) and their joint effect
(multivariate analysis) on RFS and OS was investigated using a
Cox regression model. The CEA score was analysed as a contin-
uous variable. As the CEA score distribution was positively
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skewed, the logarithmic transformation was adopted. The relation-
ship of CEA score to clinical outcome was investigated, resorting
to a regression model based on restricted cubic splines. The most
complex model considered was a four-node cubic spline, with
nodes located at the quartiles of the distribution of the CEA score
(Durrelman and Simon, 1989). The contribution of non-linear
terms was evaluated by the likelihood ratio test (LRT). Patient's
age was dichotomized adopting a cut-off point of 55 years (corre-
sponding in our series to the median age). In the Cox regression
model each ofthe regression coefficients (3) is the logarithm ofthe
hazard ratio (HR), which is assumed constant in time. Under the
null hypothesis that a variable has no prognostic role on RFS and
OS, HR is expected to be 1.00. The hypothesis of HR = 1.00 was
tested by the Wald statistic. As our patients received different
schedules ofadjuvant treatment we performed a statistical analysis
separately for each of the following subgroups: subgroup I (87
patients node-negative not treated); subgroup 11(81 patients node-
positive treated with CMF or with both CMF and TAM); and
subgroup III (65 patients node-positive treated with TAM).
Because of the relatively low number of events in the consid-
ered subgroups, to avoid overparametrization, a multivariate
analysis was performed only for subgroups of homogeneously
treated node-positive treated patients. In the initial model we
included the CEA score and all the variables that were statistically
significant (alpha = 10%) in the univariate analysis. The only
interaction retained as clinically relevant was CEA score x ER
status. This interaction was first investigated in a bivariate fashion
resorting to a Cox model including the main effects and the first-
order interaction term. A final more parsimonious model was then
obtained using a backward selection procedure that retained only
the variables reaching the conventional significance level of 5%
(final model). The impact of each variable on clinical outcome in
addition to that of the remaining variables was assessed by means
ofthe LRT. In the final model the CEA score was retained, regard-
less of statistical significance. In both univariate and multivariate
analyses for independent dichotomous variables, the putative
better prognosis category was considered as the reference cate-
gory. We evaluated the predictive capacity of the final model and
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Figure 1 Strong and diffuse CEA immunostaining in the cytoplasm of an
infiltrating ductal carcinoma of the breast
mean ofHarrell c statistics (Harrell et al, 1982). Ifthe model has no
predictive capacity (i.e. the variables are not useful discriminators
ofoutcome) the statistic c is expected to be 0.5, whereas it tends to
be 1.00 in the case ofhigh prognostic capacity. To aid the clinical
reader to interpret the value ofthis statistic, we suggest that values
between 0.6 and 0.7 be considered as indicating a weak predictive
capacity, values between 0.71 and 0.8 a satisfactory predictive
capacity and values greater than 0.8 a good predictive capacity.
RESULTS
CEA immunohistochemistry and its association with
the other features
CEA immunohistochemistry was always cytoplasmic; staining
intensity was variable and heterogeneous (Figure 1). In the overall
series of breast carcinomas, CEA-reactive cells were seen in 114
(45.2%) cases. The percentage ofCEA-reactive cells ranged from
0% to 95% of tumour cells; the median percentage of CEA reac-
tive cells was 0. The CEA score ranged from 0 to 285, with median
of 0. CEA immunoreactivity was seen in all types of infiltrating
Table 2 Univariate analysis of relapse free survival and overall survival in the series of patients node-negative not treated with adjuvant therapy
Variables Relapse-free survival Overall survival
ba s.e.b X2 Wald P-value ba s.e.b X2 Wald P-value
Log CEA score
Continuous 0.092 0.095 0.95 0.33 0.246 0.14 2.92 0.09
Histotype
Otherc vs ductal* -0.619 0.63 0.98 0.32 -0.963 1.06 0.83 0.36
Grading
G3 vs G1/2* 0.792 0.44 3.27 0.07 1.33 0.70 3.69 0.05
Age
> 55 years vs < 55 years* 0.651 0.46 0.95 0.15 0.201 0.64 0.98 0.75
Pathological tumour size
pT2/3 vs pTl 0.917 0.46 4.02 0.04 0.824 0.63 1.66 0.20
ERd
Negative vs positive* 0.301 0.54 0.44 0.50 0.740 0.67 1.21 0.27
ab, regression coefficient estimates; bs.e., standard error; ctwelve infiltrating lobular carcinomas, five medullary carcinomas, seven infiltrating tubular carcinomas,
seven mucinous carcinomas and four cribriform infiltrating carcinoma; doestrogen receptor status. *Reference category.
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Figure 2 Seven year relapse-free survival and overall survival probability
(y-axis) according to log-CEA score (x-axis). - -, Node-negative patients;
- - -, node-positive patients treated with adjuvant TAM; * *o., node-positive















Figure 4 Kaplan and Meier estimates of relapse-free survival and overall
survival probability according to grading in node-positive tumours, subdivided
according to adjuvant treatment. -, Grade 1 and 2 tumours treated with
adjuvant CMF; --, grade 1 and 2 tumours treated with adjuvant TAM; - - -,
grade 3 tumours treated with adjuvant CMF;- -, grade 3 tumours treated
with adjuvant TAM
carcinomas. No statistically significant association was seen
between CEA immunoreactivity (CEA score) and any other
clinicopathological or biological features.
............. The difference between the distribution ofCEA score within the
modalities of the other dichotomous variables considered was not
statistically significant, as indicated using the Kolmogorov-
Smirnov test: tumour size (pT 2/3 vs pT 1, KST = 0.41, P = 0.96);
histotype (other vs ductal, KST = 0.63, P = 0.82); nodal status
72 84 (positive vs negative, KST = 0.64, P = 0.80); histological grading
(G3 vs GI/2, KST = 0.33, P = 0.99); age (> 55 years vs < 55 years);
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Figure 3 Kaplan and Meier estimates of relapse-free survival and overall
survival probability according to grading in node-negative patients.
Grade 1 and 2 tumours; - - -, grade 3 tumours
Clinical outcome of the patients
At a median follow-up time of 84 months (range 6-140 months)
and 86 months (range 11-140 months), the probability of RFS and
OS of the overall series was 62% and 71% respectively. Recurrent
disease was seen in 95 patients (24 out of 104 node-negative, 46 out
of 81 node-positive CMF or CMF + TAM treated and 25 out of 65
TAM treated), whereas 77 patients died (13 node-negative, 34
node-positive CMF or CMF + TAM treated and 30 node-positive
TAM treated). Among node-negative patients 5-year RFS and OS
were 78% and 92% respectively; among node-positive patients RFS
and OS were 49% and 57% respectively. Five-year RFS and OS for
node-positive patients treated with adjuvant chemotherapy (in eight
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Table 3A Univariate analysis of relapse-free survival and overall survival in the series of patients node-positive treated with adjuvant hormonal therapy
Variables Relapse-free survival Overall survival
ba s.e.b %2 Wald P-value be s.e.b X2 Wald P-value
Log CEA score
Continuous -0.015 0.095 0.02 0.88 -0.005 0.09 0.0039 0.95
Histotype
Otherc vs ductal* -0.138 0.74 0.03 0.85 -0.189 0.73 0.066 0.796
Grading
G3 vs G1/2* 0.812 0.51 2.58 0.108 0.550 0.42 1.75 0.186
Age
> 55 years vs < 55 years* 1.206 0.55 4.79 0.028 -1.016 0.50 4.07 0.043
Number of involved nodes
.3 vs <3* 0.470 0.40 1.33 0.25 0.900 0.39 5.19 0.023
Pathological tumour size
pT2/3 vs pTl 0.616 0.47 1.73 0.189 0.164 0.39 0.17 0.677
ERd
Negative vs positive* 1.303 0.43 9.17 0.002 1.155 0.39 8.58 0.0033
ab, regression coefficient estimates; bs.e., standard error; ctwelve infiltrating lobular carcinomas, five medullary carcinomas, seven infiltrating tubular carcinomas,
seven mucinous carcinomas and four cribriform infiltrating carcinoma; doestrogen receptor status. *Reference category.
Table 3B Univariate analysis of relapse-free survival and overall survival in the series of patients node-positive treated with systemic adjuvant chemotherapy
Variables Relapse-free survival Overall-survival
ba s.e.b x2 Wald P-value ba s.e.b x2 Wald P-value
Log CEA score
Continuous -0.085 0.07 1.41 0.23 -0.118 0.09 1.93 0.16
Histotype
Otherc vs ductal* -0.080 0.44 0.03 0.85 0.142 0.48 0.09 0.77
Grading
G3 vs G1/2* 0.826 0.39 4.39 0.036 1.202 0.54 5.01 0.025
Age
> 55 years vs < 55 years* 0.033 0.44 0.005 0.941 0.400 0.45 0.791 0.37
Number of involved nodes
.3 vs <3* 1.078 0.35 9.51 0.002 0.857 0.41 4.43 0.03
Pathological tumour size
pT2/3 vs pT1* 1.330 0.39 11.48 <0.001 2.397 0.73 10.77 0.001
ERd
Negative vs positive* 0.388 0.32 1.46 0.23 0.447 0.37 1.41 0.235
ab, regression coefficient estimates; bs.e., standard error; c twelve infiltrating lobular carcinomas, five medullary carcinomas, seven infiltrating tubular
carcinomas, seven mucinous carcinomas and four cribriform infiltrating carcinoma; doestrogen receptor status. *Reference category.
cases associated with hormonal therapy) were 44% and 57%
respectively; 5-year RFS and OS for node-positive patients treated
with adjuvant hormonotherapy were 59% and 57% respectively.
Prognostic value of CEA score and of other features
Univariate survivalanalysis
In all the considered subgroups, forboth RFS and OS a linear rela-
tionship between the logarithm of the hazard and log-CEA score
was found to be appropriate. In the node-negative patients who
were not treated with adjuvant therapy (Table 2), the CEA
score was weakly significant for OS (P = 0.09) but not for RFS
(P = 0.33) (Figure 2). Histological grading (G3 vs G1/2) was
significantly predictive for OS and RFS (Figure 3), whereas
tumour size (pT2/3 vs pTl) was prognostically significant only for
RFS. Among node positive patients treated with systemic adjuvant
hormonal therapy (Table 3A), the only variables associated with
RFS and OS were ER status (negative vs positive) and age
(> 55 years vs < 55); the number of involved nodes (2 3 vs < 3)
was of prognostic value only for OS. Among node-positive
patients treated with systemic adjuvant chemotherapy (Table 3B),
the following variables were statistically significant both for RFS
and for OS: number of involved nodes, tumour size and histo-
logical grading (Figure 4).
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Table 4A Multivariate analysis (final model) of relapse-free survival in the
series of patients node-positive treated with adjuvant hormonal-therapy
Variables ba s.e.b %2 Wald P-value X2 Wald
Log CEA score
Continuous 0.064 0.095 0.46 0.496
ERc
Negative vs positive* 1.376 0.440 9.60 0.00194
ab, regression coefficient estimates; bs.e., standard error; coestrogen receptor
status. *Reference category.
Table 4B Multivariate analysis (final model) of relapse-free survival in the
series of patients node-positive treated with systemic adjuvant chemotherapy
Variables ba s.e.b %2 Wald P-value X2 Wald
Log CEA score
Continuous -0.072 0.071 1.002 0.316
Number of involved nodes
23 vs <3* 0.939 0.353 7.06 0.0078
Pathological tumour size
pT2/3 vs pT1* 1.226 0.396 9.56 0.002
ab, regression coefficient estimates; bs.e., standard error. *Reference
category.
Table 5A Harrell c statistic in relapse-free survival for node-positive patients
treated with adjuvant hormonal therapy
Full model 0.68
Without each of the following variables
Log CEA-score 0.68
ER status 0.51
Table 5B Harrell c statistic in relapse-free survival for node-positive patients
treated with systemic adjuvant chemotherapy
Full model 0.72
Without each of the following variables
Log CEA-score 0.70
Number of involved nodes 0.68
Pathological tumour size 0.64
Multivariate analysis
To assess thejoint role ofthe variables, a multivariate Cox analysis
was carried out in the series of node-positive patients treated with
adjuvant hormonal therapy and in those treated with chemotherapy
(Table 4A and 4B respectively). Only RFS wasinvestigated because
of the limited number of events in OS. The first-order interaction
term of CEA score (linear term) and ER status was not statistically
significant in both the subgroups ofpatients. In the initial model for
CMF-treated patients, the following variables were included: CEA
score; histological grading; number of involved nodes; and patho-
logical tumour size. For tamoxifen-treated patients CEA score, ER
status and age were included in the initial model. In the final multi-
variate regression model, log CEA score confirmed its lack of
prognostic value in both subgroups. The only statistically signifi-
cant indicator in tamoxifen-treated patients was ER status
(HR = 3.9, P = 0.001). The most significant predictive indicators in
CMF-treated patients were the number of involved nodes and the
size of the tumours (HR = 2.56, P = 0.005; HR = 3.41, P < 0.001
respectively).
Predictive capability ofthe clinicopathological variables
The overall capability of the variables in the final regression
model to predict RFS was weak for tamoxifen-treated patients
(c = 0.68) and moderate for CMF-treated patients (c = 0.72). The
contribution of each variable is shown in Table 5. The highest
predictive capability was given by the number of involved nodes
for CMF-treated patients and by the ER status for tamoxifen-
treated patients. The contribution ofthe other variables in both the
considered multivariate models was less relevant.
DISCUSSION
The current study evaluates CEA immunostaining in breast carci-
noma using the highly specific T84.66 monoclonal antibody. This
antibody does not cross-react with other members of the CEA
family, and is a reliable tool to investigate CEA expression at the
immunohistochemical level. To the best of our knowledge, this
antibody has been used only in a few other studies on breast carci-
noma (Esteban et al, 1994; Sundblad et al, 1996).
In our series of 252 breast carcinomas, CEA immunostaining
was seen in 45% of cases. This is only slightly lower than the
percentages found by other studies using the same antibody, which
have reported 56% (Sundblad et al, 1996) and 58% (Esteban et al,
1994) CEA immunoreactivity. In our series the distribution of
CEA expression within the modalities of the other clinicopatho-
logical or biological variables was not found to be statistically
significant. We evaluated with particular attention the two variables
CEA and ER, but the possibility ofa statistical interaction between
them was ruled out by several methods (data not shown in detail).
This is in keeping with the study ofSundblad et al (1996), but is at
variance with the study performed by Esteban et al (1994), which
reported an association between CEA expression and positive ER
status. A positive association between CEA and ER status has
been found by other studies that used different CEA antibodies
and/or different methods to identify CEA expression, such as
immunoradiometric (Gion et al, 1986) or immunofluorimetric
(Levesque et al, 1994) procedures on cytosolic tumour extracts.
In our hands, CEA expression was not a statistically significant
prognostic factor, both in the whole series of patients (data not
shown) and in the various groups of patients subdivided on the
basis of nodal status and/or adjuvant therapy. In the present study
we report the data using the CEA score as a continuous variable,
but similar results were observed using the variable 'percentage of
CEA reactive cells' as dichotomous on the basis of the cut-off
point suggested by the other authors (data not shown) (Esteban
et al, 1994; Sundblad et al, 1996).
The prognostic role of CEA immunohistochemical expression,
even using the same T84.66 antibody, seems a controversial issue:
Esteban et al (1994) found that CEA expression was not prognosti-
cally relevant, except in subsets ofcases subdivided on the basis of
ER status, whereas Sundblad et al (1996) found that CEA expres-
sion was an independent marker of prolonged DFS. It seems
difficult to explain the reasons of these discrepancies: technical
artefacts, differences in case selection or a bias due to the relatively
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small number ofinvestigated cases in each study may be the major
factors implicated. To rule out technical artefacts due to differences
in fixation or immunohistochemical staining, a pilot series of
our cases has also been immunostained in the Laboratory of
Dr Battifora, who raised the antibody and was the senior author of
the paperofEsteban et al (1994). The immunohistochemical results
obtained in the laboratory of Dr Battifora and in our laboratory
were identical, suggesting that technical artefacts should not be a
major problem in the present series. Conversely, case selection in
the above studies seems to be different: age of the patients, tumour
grade and tumour size are indeed different. In the study ofEsteban
et al (1994) and in our study, 30% and 36% ofthe patients, respec-
tively, were younger than 50 years compared with only 8% in the
series of Sundblad et al (1996). In the study of Sundblad et al
(1996) there were 78% pT2 tumours, whereas in our present series
and in the study of Esteban et al (1994) there were 43% and 52%
pT2 neoplasms respectively. The similarity ofseveral parameters in
our patients and Esteban's series of patients and the remarkable
differences with the series of Sundblad et al (1996) may partially
explain why we both found that CEA per se is not a statistically
significant prognostic factor and why Sundblad et al (1996) found it
to be significant.
In our present study, we could not reproduce the results of
Esteban's group concerning the interaction between CEA and ER
status: we could not demonstrate any interaction between the two
variables and, stratifying patients on the basis of the ER status
(data not shown), we could not find any statistically significant
prognostic value for CEA immunostaining.
Considering our present results as shown in Figure 2, it can be
observed that there is a non-statistically significant trend for
prolonged survival in node-negative cases with low CEA expres-
sion (see also Table 2; P = 0.33 for RFS and P = 0.09 for OS);
conversely, an opposite trend was seen in node-positive patients
treated with adjuvant chemotherapy (see also Table 3; P = 0.23 for
RFS and P = 0.16 for OS), whereas in node-positive patients treated
with hormonal therapy survival remained constant, regardless of
the CEA score. These data, showing slight differences in survival
depending upon stage and adjuvant treatment, are not completely
comparable with the studies of Sundblad et al (1996) and Esteban
et al (1994), who did not perform a separate analysis for homoge-
neously staged and treated patients and did not describe whether
patients received any adjuvant treatment. Esteban et al (1994)
reported that low CEA expression was associated with higher risk
of death in the ER-negative subgroup, which is the group of
breast cancer patients more frequently treated with adjuvant
chemotherapy. It could be hypothesized that patients with high
CEA expression could benefit more from chemotherapy than cases
with low or absent CEA immunostaining. Further studies on larger
series of homogeneous stage breast cancers are needed to analyse
the prognostic value of CEA immunostaining, especially by
analysing large subsets ofhomogeneously treated patients.
The present data further support the prognostic value of tradi-
tional pathological parameters, including tumour grade. Tumour
grading according to Elston and Ellis (1991) is a reproducible,
cost-effective and reliable tool for predicting tumour behaviour.
The possibility ofcoupling the effects oftumour size, nodal status
and tumour grade into the Nottingham prognostic index can
further improve the prognostic power of classical pathological
parameters (Todd et al, 1987). However, it is true that, although it
is quite easy to predict the outcome of patients with the best and
worst prognosis, there is still a large percentage of patients with a
much more undetermined prognosis for which the search for addi-
tional biological prognosticators may be ofclinical use.
Concerning the other parameters evaluated in the present study
in relation to adjuvant therapy, we could confirm that ER immuno-
histochemical status was prognostically relevant in node-positive
patients receiving hormonal therapy; conversely ER status was not
prognostically useful among node-negative patients, who in the
majority of cases were not treated with adjuvant therapy, and in
node-positive patients receiving chemotherapy. These data are in
keeping with the hypothesis that ER status as determined using
immunohistochemical methods represent an important marker for
predicting therapeutic response to adjuvant systemic therapy
(Veronese et al, 1995; ASCO, 1996). The capability to predict
therapeutic response is indeed one of the most exciting fields of
clinical research: the therapeutic effect ofadjuvant therapy is rela-
tively small, and any effort should be made to use chemotherapy in
a selective way to maximize the benefit to the individual patient
while sparing unnecessary side-effects to patients who will not
respond to therapy. ER status is actually the most reliable predic-
tive marker, but there is indeed the need to find additional markers
to couple with it to better define individual patient's characteristics.
Whether CEA immunoreactivity will also prove to be an inter-
esting marker in this respect, as suggested by Esteban et al (1994),
is still to be verified (Hayes et al, 1996), but our present data do not
seem very encouraging.
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